efficacy of tirzepatide for the treatment adults with type 2 diabetes: An endocrine perspective Efficacy and Safety of Tirzepatide

The lack of functional characterization for several SiOBPs represents a critical knowledge gap that may conceal yet-unexplored targets for semiochemical-based management

In a Phase 1 trial, three once-monthly injections of 420 mg of maridebart cafraglutide in overweight/obese individuals without diabetes reduced body weight by 14%, and most of the weight loss was maintained for 23 months after treatment was discontinued [54]

Dexras1, a small gtpase, is required for glutamate-nmda neurotoxicity

The research literature and clinical practice provide guidance, but individual response varies

In April 2020, Verdoni et al

Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-proteincoupled receptor FFAR2